

First World Conference on

Targeting Liver Diseases

June 26-27, 2014

Dan Hotel – Jerusalem, Israel

First World Conference on

החברה הישראלית
לחקר הכבד
Israel Association for the
Study of the Liver



Targeting Liver Diseases



June 26-27, 2014 Hadassah Medical Center - Jerusalem, Israel

Scientific Program



1st World Conference on
Targeting Liver Diseases

June 26-27, 2014 - Jerusalem, Israel



www.targeting-liver.com

First World Conference on
Targeting Liver Diseases

June 26-27, 2014

Dan Hotel – Jerusalem, Israel

Dear Colleagues,

It is a great pleasure to welcome you for the **First World Conference on Targeting Liver Diseases: Sciences, Clinical Innovation & Biotechnology** to be held in **Jerusalem** in **June 26-27, 2014**.

This conference is co-organized by the Israeli Association for the Study of Liver and Targeting Mitochondria Task Force Group.

"Liver mitochondria" was one of the strategic topic during the Targeting Mitochondria 2013 meeting which in Berlin. Many studies demonstrated that mitochondria alteration and dysfunction were strongly involved in liver diseases. Targeting Liver Mitochondria was focused in this meeting as an important key to prevent, diagnose and treat liver diseases. On behalf of all specialists working in all liver fields, we agreed to gather for an **interactive discussion of recent scientific advances, the clinical studies and innovations**. *We should think out of the box as well!*

During Targeting Liver 2014, we will initiate new channels and fields such as Microbiota, Stem Cells, Mitochondria and wave them to liver homeostasis and pathologies.

A large time will be allocated to innovations and biotechnologies in the world of liver. Numerous pharmaceutical companies, start ups, academic and scientific teams will be invited to present their innovations, devices to evaluate liver functions, new biomarkers, stem cells modulations, drugs in development for combating, preventing and curing liver diseases and liver related conditions.

Among Sessions of Targeting Liver Diseases 2014

- **Liver Diseases 2014: The mechanistic**
 - *Cellular & Molecular Mechanisms*
- **Bio-markers and liver: State of the art and innovations**
 - *New devices & biotechnologies to evaluate liver dysfunctions*
 - *New non invasive methods to evaluate liver*
- **Targeting Liver Mitochondria**
 - *Liver diseases, redox modulation & Oxidative stress: the subtle balance*
 - *Strategies to overcome liver dysfunctions by antioxidants: controversies and credibility*
 - *Silymarin, Curcumin, polyphenols and other antioxidants in the prevention and treatment of liver diseases and primary liver cancer*
- **Liver Diseases & drugs in development**
- **Liver and Innovations**
 - *Liver & Microbiota*
 - *Liver & Stem Cells*
 - *Liver Transplantation*

A Special Symposium will be dedicated to liver & diabetes with a discussion about this vicious circle.

We look forward welcoming you in lovely Jerusalem next June.



Prof. Marvin Edeas
Chairman of Targeting Mitochondria
Task Force Group



Prof. Rifaat Safadi
Chairman of Local Organizing
Committee

First World Conference on
Targeting Liver Diseases

June 26-27, 2014 - Dan Hotel – Jerusalem, Israel

Conference Chairmen : **M. Edeas, B. Fuhrman, K. Kaestner, R. Lakshman,
A. Nimer, R. Oren, R. Safadi, O. Tirosh**

Day 1 - June 26, 2014

08h00 - 08h55 Welcoming of Attendees

09h00 Welcome Note by Chairmen of Scientific Committee
Pr Marvin Edeas / Pr Rifaat Safadi

Session 1: Liver Diseases 2014: The Mechanistic

09h05 The Role of NLG4 between Insulin Resistance and Innate Immunity in Fatty Liver Disease
Rifaat Safadi, Hadassah Medical Center, Jerusalem, Israel

09h30 Mitochondria-Microbiota: The Intriguing Relationship: The future of Medicine coming through Bacteria
Marvin Edeas, Chairman of Targeting Mitochondria Task Force Group, Paris, France

10h00 Anti-Oxidants in Liver Disease: Recent Advances and Perspectives
Oren Shibolet, Liver Unit, Tel-Aviv Medical Center, Tel-Aviv Israel

10h25 Coffee Break & Posters Session

10h55 Role of the Nitric Oxide Signaling in Cholesterol-Induced Liver Damage
Oren Tirosh, The Hebrew University of Jerusalem, Rehovot, Israel

11h20 The Role of Specific Sphingolipids in Liver Diseases
Yael Pewzner-Jung, Weizmann Institute of Science, Rehovot, Israel

11h45 Hepatic Paraoxonase-1 (PON1) Regulation: Recent Advances & Perspectives
Bianca Fuhrman, Technion Faculty of Medicine and Rambam Health Care Campus, Haifa, Israel

12h10 Role of Lysophosphatidic Acid Receptor Dependent Signaling in Hepatic Tumor Cell Proliferation and Motility
Valentina Zuckerman, Carolinas Medical Center, Charlotte, USA

12h20 The Transforming Growth Factor-Beta Pathway Governs Human Liver Tumor Cell Plasticity and Resistance to Sorafenib
Isabel Fabregat, Bellvitge Biomedical Research Institute, Barcelona, Spain

12h30 Lunch & Posters Session

Session 2: Targeting Liver Diseases: Targets, Strategies & Innovations - Part I

14h00 The Microbiome & Liver Diseases: Towards a New Understanding
Christoph Thaiss, Weizmann Institute of Science, Rehovot, Israel

14h25 Interaction of Nutrition, Pouches, Microbiome and Oxidative Stress
Nitsan Maharshak, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

14h50 Diabetes and Liver: Recent Advances & Perspectives
Itamar Raz, Hadassah Ein Kerem Hospital, Jerusalem, Israel

15h15 Vitamin E & Diabetic Nephropathy: Lessons & Clinical Implications
Farid Nakhoul, Bar Ilan University Ramat Gan, Lower Galilee, Israel

15h40 Coffee Break & Posters Session

- 16h10 **Obesity and Liver: Are Dietary Polyphenols Adipose Tissue Modulators?**
Yishai Lévy, Rambam Health Care Campus, Bat Galim, Haifa, Israel
- 16h35 **Stellate Cells in Hepatic Fibrogenesis and Protection by a Novel Modulator**
Raj Lakshman, The George Washington University, Washington, USA
- Short Oral Presentations selected by Scientific Committee (7 + 3 minutes)*
- 17h00 **Autophagy Induces Activation of Hepatic Stellat Cells during Incubation with TGF- α 1**
Lieming Xu, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
- 17h10 **The uPA / uPAR System Contributes to the Development of the Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease**
Nicole Paland, Technion-Israel Institute of Technology, Haifa, Israel
- 17h20 **Inflammation Induced Hepatocellular Carcinoma is Dependent on CCR5**
Neta Barashi, Hadassah Hebrew University Hospital, Jerusalem, Israel
- 17h30 **Thyroid Hormone Activates FoxO1 Transcription Factor via SirT1-AKT Pathway**
Brijesh Kumar Singh, Duke-NUS Graduate Medical School, Singapore
- 17h40 **Thyroid Hormone Stimulation of Hepatic Mitochondrial Activity Requires Mitophagy**
Rohit A. Sinha, Duke-NUS Graduate Medical School, Singapore
- 17h50 **Senescence-Related Gene Signatures as Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma**
Mehmet Ozturk, Bilkent University Department of Molecular Biology and Genetics, Ankara, Turkey
- 18h00 **The Association of Non-Alcoholic Fatty Liver Disease with Cardiovascular Risk Factors: Findings From a Population Based Cohort**
Patel Sumaiya, University of Bristol, Bristol, United Kingdom
- 18h10 **Infiltrating Monocyte-Derived Macrophages and Resident Kupffer Cells Display Different Ontogeny and Functions in Acute Liver Injury**
Chen Varol, Tel Aviv University, Tel Aviv, Israel
- 18h20 **End of First Day**
- 20h00 **Dinner between Speakers & Attendees** - *You can register to the dinner with the form online.*
-

Day 2 - June 27, 2014

Session 2: Targeting Liver Diseases: Targets, Strategies & Innovations - Part II

- 09h00 **Targeting IL-6 and STAT3 Signaling in Liver Cancer**
Jonathan Axelrod, Hadassah Hebrew University Hospital, Jerusalem, Israel
- 09h25 **Inflammation & NAFLD: Recent Advances & Perspectives**
Ran Oren, Hadassah Medical Center, Jerusalem, Israel
- 09h50 **Liver Repopulation Following Toxic Liver Injury - Which Genes Have Most Impact?**
Klaus H. Kaestner, University of Pennsylvania School of Medicine, Philadelphia, USA
- 10h15 **Converting Liver to Pancreas- Cell Replacement Therapy for Diabetes**
Sarah Ferber, Sheba Medical Center, Tel-Hashomer, Israel

10h40 Coffee Break & Posters Session

Session 3: Liver Diseases & Drugs in Development

- 11h00 **Update in Managing Viral Hepatitis**
Assy Nimer, Ziv Medical Center, Safed, Israel

Short Oral Presentations selected by Scientific Committee (7 + 3 minutes)

- 11h20 Biengineering Livers for Transplantation**
Shay Soker, Institute for Regenerative Medicine, Winston-Salem, USA
- 11h30 Mathematical Modeling of the Liver Metabolism under Normal and Pathophysiological Conditions**
Hermann-Georg Holzhütter, Charité – Universitätsmedizin, Berlin, Germany
- 11h40 Human Cell Responses during Initial Steps of Hepatic Infection with *Entamoeba Histolytica*, the Etiological Agent of Amoebiasis**
Daniela Faust, Institut Pasteur, Paris, France
- 11h50 Protection Exerted by Levosimendan against Liver Peroxidative Injuries**
Elena Grossini, University East Piedmont "A. Avogadro"; Experimental Surgery, Novara, Italy
- 12h00 Mutations of Nrf2 are an Early Event in Experimental Hepatocarcinogenesis**
Amedeo Columbano, University of Cagliari, Cagliari, Italy
- 12h10 Role of Adiponectin in the Antisteatotic Effect of Cannabinoid-1 (Cb1) Receptor Blockade**
Yossi Tam, The Hebrew University of Jerusalem, Jerusalem, Israel
- 12h20 Anti-Proliferative Effects of Bilirubin and Related Algal Tetrapyrroles**
Libor Vítek, Charles University, Prague, Czech Republic
- 12h30 Different Effects of the Short-Term and Long-Term S-Adenosylmethionine Supplementation on Tumor Development in a Chronically Inflamed Murine Liver**
Daniel Goldenberg, Hadassah- Hebrew University Medical Center, Jerusalem, Israel
- 12h40 Evaluation of Undiagnosed Liver Masses, Not Exhibit Typical Imaging Features But HCC, even HCC with Stage C**
Metin Basaranoglu, Türkiye Yüksek İhtisas Hospital . Gastroenterology Clinic. Ankara, Turkey
- 12h50 Discussion & Conclusion of Targeting Liver Diseases 2014 Conference**
Targeting Liver Diseases 2014 Scientific Award

13h 15 Lunch & Posters Session
End of Targeting Liver Diseases 2014 Conference